trans 1,4-diisopropoxy-2-butene | 139111-17-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: trans 1,4-diisopropoxy-2-butene
• 英文别名: (E)-1,4-di(propan-2-yloxy)but-2-ene
• CAS: 139111-17-4
• 化学式: C₁₀H₂₀O₂
• 分子量: 172.268
• InChiKey: SOTWQKWPJWXFPK-AATRIKPKSA-N

物化性质

• 沸点：
  208.2±28.0 °C(Predicted)
• 密度：
  0.858±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  甲醇 、 trans 1,4-diisopropoxy-2-butene 、 异丙醇 以1.8 mmol of 1,3-diisopropoxy-3-butene and 9.7 mmol of cis + trans 1,4-diisopropoxy-2-butene were obtained的产率得到1,3-diisopropoxy-3-butene
  参考文献：
  名称：

  Preparation of dialkoxybutenes

  摘要：

  通过在氧气和催化有效量的固体颗粒的存在下，将1,3-丁二烯与醇反应，可以高收率地选择性制备二烷氧基丁烯。所述固体颗粒包括沉积在其支撑颗粒上的催化活性相，所述催化活性相包括至少一种第一组VIII族贵金属成分、至少一种碲、硒和/或硫第二组成分，以及可选地至少一种第三组成分，包括铋、锑、铜和/或锡。

  公开号：

  US05159120A1
• 作为产物：
  描述：

  1-环戊烯甲醛 在 silica gel 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 乙烯 、 trans 1,4-diisopropoxy-2-butene
  参考文献：
  名称：

  Herrmann, Wolfgang A.; Wagner, Werner; Flessner, Uwe N., Angewandte Chemie, 1991, vol. 103, # 12, p. 1704 - 1706

  摘要：

  DOI：

文献信息

• Benzimidazole derivatives
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10017499B2

  公开（公告）日：2018-07-10

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物或其药学上可接受的盐、酯或原药： 它们能抑制含 RNA 的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物可干扰丙型肝炎病毒的生命周期，也可用作抗病毒药物。本发明进一步涉及包含上述化合物的药物组合物，用于给丙型肝炎病毒感染者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者感染 HCV 的方法。
• LINKED DIBENZIMIDAZOLE DERIVATIVES
  申请人：Or Yat Sun

  公开号：US20100221214A1

  公开（公告）日：2010-09-02

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：Qiu Yao-Ling

  公开号：US20100233122A1

  公开（公告）日：2010-09-16

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• HEPATITIS C VIRUS INHIBITORS
  申请人：Or Yat Sun

  公开号：US20100260715A1

  公开（公告）日：2010-10-14

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US20140341851A1
  申请人：——

  公开号：US20140341851A1

  公开（公告）日：2014-11-20